Psychiatr. praxi. 2011;12(4):149-152

Acute treatment of bipolar depression

doc.MUDr.Radovan Přikryl, Ph.D.
Ceitec-MU, Psychiatrická klinika LF MU a FN Brno

In the last years new data have been published on the acute treatment of depression of bipolar affective disorder. They have been subsequently

involved in the guidelines and treatment algorithms of bipolar affective disorder. Unfortunately, they often led to conflicting

conclusions and recommendations due to limitations of the available literature. As a general approach during depressive episodes in

bipolar disorder most guidelines suggest lithium, lamotrigine or quetiapine monotherapy as first-line choice. If psychotic features are

present, to add an antipsychotic such as olanzapine, quetiapine or risperidone. The use of an antidepressant with caution, always in

combination with quetiapine, lamotrigine or mood stabilizer. Although guidelines cannot substitute professional knowledge and clinical

judgement, they might be a useful tool for clinicians in order to orientate their practice towards evidence base.

Keywords: bipolar depression, guideline, lamotrigine, treatment, lithium, olanzapine, quetiapine, review, valproate

Published: October 22, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Přikryl R. Acute treatment of bipolar depression. Psychiatr. praxi. 2011;12(4):149-152.
Download citation

References

  1. Nivoli AMA, Colom F, Murru A, et al. New treatment guidelines for acute bipolar depression: A systematic review. Journal of Affective Disorders 2011; 129: 14-26. Go to original source... Go to PubMed...
  2. Calabrese JR, Keck Jr PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry 2005; 162: 1351-1360. Go to original source... Go to PubMed...
  3. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a doubleblind, placebo-controlled study (the BOLDER II study). J. Clin. Psychopharmacol. 2006; 26: 600-609. Go to original source... Go to PubMed...
  4. Young AH, Carlsson A, Olausson B, et al. A double-blind, placebo controlled study with acute and continuation phase of quetiapine and lithium in adults with bipolar depression (EmboldenI). Bipolar Disord. 2008; 10: 1-451. Go to original source...
  5. McElroy SL, Young AH, Carlsson A, et al. A double-blind, placebo-controlled study with acute and continuation phase of quetiapine and paroxetine in adults with bipolar depression (EMBOLDEN II). Bipolar Disord. 2008; 10: 1-59. Go to original source...
  6. Sokolski KN, Denson TF. Adjunctive quetiapine in bipolar patiens partially responsive to lithium or valproate. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003; 27: 863-866. Go to original source... Go to PubMed...
  7. Suppes T, Kelly DI, Keck Jr. PE, et al. Quetiapine for the continuation treatment of bipolar depression: naturalistic prospective case series from the Stanley Bipolar Treatment Network. Int. Clin. Psychopharmacol. 2007; 22: 376-381. Go to original source... Go to PubMed...
  8. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry 2003; 60: 1079-1088. Go to original source... Go to PubMed...
  9. Grunze H, Vieta E, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J. Biol. Psychiatry 2009; 10: 85-116. Go to original source... Go to PubMed...
  10. Grunze H, Vieta E, Goodwin GM, et al. WFSBP task Force on treatment guidelines for bipolar disorders. The World Federation of Societies of Biological Psychiatry (WFSBP Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. The World Journal of Biological Psychiatry 2010; 11: 81-109. Go to original source... Go to PubMed...
  11. NICE clinical guidelines. Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Institute for Health and Clinical Excellence, update 2009.
  12. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009; 11: 225-255. Go to original source... Go to PubMed...
  13. Goodwin GM. Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition - recommendations from the British Association for Psychopharmacology Journal of Psychopharmacology. J. Psychopharmacol. 2009; 23: 346-388. Go to original source... Go to PubMed...
  14. Goodwin GM, Anderson I, Arango C, et al. ECNP consensus meeting. Bipolar depression. Nice, March 2007. Eur. Neuropsychopharmacol. 2008; 18: 535-549. Go to original source... Go to PubMed...
  15. Raboch J, Anders M, Hellerová P, Uhlíková P (eds.) Psychiatrie: Doporučené postupy psychiatrické péče III. Tribun EU; 2010: 118-126.
  16. Kasper S, Calabrese JR, Johnson G, et al. International Consensus Group on the Evidence-Based Pharmacological Treatment of Bipolar I and II Depression. J. Clin. Psychiatry 2008; 69: 1632-1646. Go to original source... Go to PubMed...
  17. Pacchiarotti I, Mazzarini L, Colom F, et al. Treatment-resistant bipolar depression: towards a new definition. Acta Psychiatr. Scand. 2009; 120(6): 429-440. Go to original source... Go to PubMed...
  18. Smith LA, Cornelius V, Warnock A, et al. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord. 2007; 9(4): 394-412. Go to original source... Go to PubMed...
  19. Bowden CL, Calabrese JR, Sachs G, et al. Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psychiatry 2003; 60(4): 392-400. Go to original source... Go to PubMed...
  20. Calabrese JR, Bowden CL, Sachs G, et al. Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J. Clin. Psychiatry 2003; 64: 1013-1024. Go to original source... Go to PubMed...
  21. Geddes J, Goodwin G, Rendell J, et al. New trial should clarify lithium use in bipolar disorder. BMJ 2002; 325(7361) 441. Go to original source...
  22. Baldessarini RJ, Tondo L. Does lithium treatment still work? Evidence of stable responses over three decades. Arch. Gen. Psychiatry 2000; 57(2): 187-190. Go to original source... Go to PubMed...
  23. Van der Loos ML, Mulder PG, Hartong EG, et al. LamLit Study Group. Efficacy and safety of lamotrigine as addon treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2009; 70: 223-231. Go to original source... Go to PubMed...
  24. Calabrese JR, Bowden CL, McElroy SL, et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am. J.Psychiatry 1999; 156: 1019-1023. Go to original source... Go to PubMed...
  25. Calabrese JR, Shelton MD, et al. Long term treatment of bipolar disorder with lamotrigine. J. Clin. Psychiatry 2002; 63(Suppl 10): 18-22.
  26. Brown EB, McElroy SL, Keck Jr PE, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J. Clin. Psychiatry 2006; 67: 1025-1033. Go to original source... Go to PubMed...
  27. Brown E, Dunner DL, McElroy SL, et al. Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. Int. J. Neuropsychopharmacol. 2008: 1-10. Go to original source... Go to PubMed...
  28. Frye M, Ketter T, Kimbrell TA, et al. A placebo controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J. Clin. Psychopharmacol. 2000; 20: 607-614. Go to original source... Go to PubMed...
  29. Calabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo controlled clinical trials. Bipolar Disord. 2008; 10: 323-333. Go to original source... Go to PubMed...
  30. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis andmeta-regression of individual patient data from five randomised trials. Br. J. Psychiatry 2009; 194: 4-9. Go to original source... Go to PubMed...
  31. Ghaemi SN, Gilmer WS, Goldberg JF, et al. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J. Clin. Psychiatry 2007; 68: 1840-1844. Go to original source... Go to PubMed...
  32. Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J. Affect. Disord. 2005; 85: 259-266. Go to original source... Go to PubMed...
  33. Sachs G, Collins MA, Altshuler L, et al. Divalproex sodium versus placebo for the treatment of bipolar depression. APA 2002 Syllabus & Proceedings Summary.
  34. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J. Med. 2007; 356: 1711-1722. Go to original source... Go to PubMed...
  35. Goldberg JF, Perlis RH, Ghaemi SN, et al. Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. Am. J. Psychiatry 2007; 164: 1348-1355. Go to original source... Go to PubMed...
  36. Ballenger JC. The clinical use of carbamazepine in affective disorder. J. Clin. Psychiat. 1998; 49(Suppl 4): 13-19.
  37. Zhang ZJ, Tan QR, Tong Y, et al. The effectiveness of carbamazepine in unipolar depression: a double blind, randomized, placebo-controlled study. J. Affect. Disord. 2008; 109(1-2): 91-97. Go to original source... Go to PubMed...
  38. McElroy SL, Weisler RH, Chang W, et al. for the EMBOLDEN II (Trial D1447C00134) Investigators. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J. Clin. Psychiatry 2010; 71: 163-174. Go to original source... Go to PubMed...
  39. Weisler RH, Calabrese JR, Thase ME, et al. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo controlled studies. J. Clin. Psychiatry 2008; 69: 769-782. Go to original source... Go to PubMed...
  40. Vieta E, Sánchez-Moreno J, Amann B. International therapeutic guidelines for bipolar disorder. Int. Clin. Psychopharmacol. 2007; 22(Suppl 1): 29-37. Go to original source... Go to PubMed...
  41. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J. Clin. Psychiatry 1994; 55: 391-393.
  42. Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am. J. Psychiatry 2006; 163: 232-239. Go to original source... Go to PubMed...
  43. McIntyre RS, Mancini DA, McCann S, et al. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord. 2002; 4: 207-213. Go to original source... Go to PubMed...
  44. Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br. J. Psychiatry 2006; 189: 124-131. Go to original source... Go to PubMed...
  45. Vieta E, Martinez-Aran A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J. Clin. Psychiatry 2002; 63: 508-512. Go to original source... Go to PubMed...
  46. Young LT, Joffe RT, Robb JC, et al. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am. J. Psychiatry 2000; 157: 124-126. Go to original source... Go to PubMed...
  47. Amsterdam J. Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode. J. Clin. Psychopharmacol. 1998; 18: 414-417. Go to original source... Go to PubMed...
  48. Amsterdam JD, Garcia-Espana F. Venlafaxine monotherapy in women with bipolar II and unipolar major depression. J. Affect. Disord. 2000; 59: 225-229. Go to original source... Go to PubMed...
  49. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord. 2003; 5: 421-433. Go to original source... Go to PubMed...
  50. Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am. J. Psychiatry 2004; 161: 1537-1547. Go to original source... Go to PubMed...
  51. Grunze HC. Switching, induction of rapid cycling, and increased suicidality with antidepressants in bipolar patients: fact or overinterpretation? CNS Spectr. 2008; 13: 790-795. Go to original source... Go to PubMed...
  52. Ghaemi SN, Bauer M, Cassidy F, et al. Diagnostic Guidelines Task Force. Diagnostic guidelines for bipolar disorder: a summary of the International Society for Bipolar Disorders Diagnostic Guidelines Task Force Report. Bipolar Disord. 2008; 10: 117-128. Go to original source... Go to PubMed...
  53. Ghaemi SN, Wingo AP, Filkowski MA, Baldessarini RJ. Long term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr. Scand. 2008; 118: 347-356. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.